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Alzheimer’s disease (AD) is the most common cause of dementia and a major contributor to disability and dependency
among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protein (Aβ) and/or
hyperphosphorylated tau protein in the brain. At present, current therapies provide temporary symptomatic benefit,
but do not treat the underlying disease. Recent research has thus focused on investigating the molecular and cellular
pathways and processes involved in AD pathogenesis to support the development of effective disease-modifying
agents. In accordance with the existing Aβ-cascade hypothesis for AD pathogenesis, immunotherapy has been the
most extensively studied approach in Aβ-targeted therapy. Both passive and active immunotherapies have been shown
to effectively reduce Aβ accumulation and prevent downstream pathology in preclinical models. Following AN1792,
second-generation active immunotherapies have shown promising results in terms of antibody response and safety.
Comparatively, tau immunotherapy is not as advanced, but preclinical data support its development into clinical trials.
Results from active amyloid-based immunotherapy studies in preclinical models indicate that intervention appears to
be more effective in early stages of amyloid accumulation, highlighting the importance of diagnosing AD as early as
possible and undertaking clinical trials at this stage. This strategy, combined with improving our understanding of the
complex AD pathogenesis, is imperative to the successful development of these disease-modifying agents. This paper
will review the active immunotherapies currently in development, including the benefits and challenges associated
with this approach.Review
Introduction
Alzheimer’s disease (AD), the most common cause of
dementia [1], is a neuropathological disorder that presents
clinically with progressive deterioration in cognitive,
memory, and functional capabilities [2]. An estimated 36
million individuals worldwide were burdened by dementia
in 2010, and this number is projected to increase to 66
million by 2030 [3,4]. The two major neuropathological
hallmarks of AD, first described by Dr Alzheimer in 1907,
are extracellular senile plaques and intracellular neuro-
fibrillary tangles (NFTs) [5]. Mutations in the amyloid
precursor protein (APP) gene, APP, and the presenilin
genes, PSEN1 and PSEN2, are strongly associated with
early-onset, familial AD and increased accumulation of
amyloid-beta protein (Aβ) [6]. In the more common
sporadic or late-onset AD, the genetic risk factor gene* Correspondence: bengt-winblad-swedishbrainpower@ki.se
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© 2014 BioMed Central Ltd.ApoE epsilon 4 increases the risk of developing the
disease [6]. These genetic lines of evidence, in com-
bination with neuropathological findings, have given
rise to the Aβ-cascade hypothesis of AD pathogenesis [7].
Although an imbalance between the production and clea-
rance of Aβ40/42 is thought to be the key initiating pa-
thology in AD, other contributing disease mechanisms
remain to be resolved.
The Aβ cascade is thought to be initiated by an elevated
Aβ concentration, in particular Aβ42, which aggregates to
form soluble dimers, trimers, and the low-ordered oligomers.
Further aggregation forms insoluble and proteolysis-resistant
fibrils, which accumulate as beta-amyloid deposits. This toxic
Aβ cascade is associated with various neuropathological
processes such as tau hyperphosphorylation, paired helical
filament accumulation, neuritic dystrophy, astrocytosis,
altered ionic homeostasis, oxidative stress, and synaptic
failure leading to progressive loss of neuronal function.
Furthermore, evidence from transgenic mice models
showed that Aβ deposition enhances tangle pathology,
consistent with the Aβ cascade hypothesis [8]. The role of
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ond neuropathological hallmark of AD, which is the pres-
ence of NFTs. Intraneuronal accumulation of abnormally
hyperphosphorylated tau is thought to impair axonal
transport, resulting in aggregation of tubules into NFTs
within the neuron and subsequent cell death [9].
Therapeutic approaches
Current therapies, such as cholinesterase inhibitors and
the N-methyl-D-aspartate receptor antagonist meman-
tine, provide temporary symptomatic benefit. Recently,
advances have been made towards developing disease-
modifying agents based on the two main hypotheses for
AD pathogenesis; that is, Aβ and tau. Immunotherapy
via administering Aβ antibodies (passive immunother-
apy) or inducing a humoral immune response (active
immunotherapy) has been the most extensively studied
approach in Aβ-targeted therapy (Figure 1). Both passive
and active immunotherapies have been shown to reduce
Aβ accumulation in transgenic mice [10-12], indicating
that interventions which reduce Aβ aggregation are
promising therapeutic options.
Passive immunotherapies with monoclonal antibodies
against Aβ are in late clinical development, but recently
bapineuzumab and solanezumab, targeting the Aβ N-
terminal and mid-domain respectively, failed to meet
their primary endpoints in cognition and activities of
daily living in phase 3 trials [13]. The clinical develop-
ment of bapineuzumab was halted in August 2012 [14].
One reason for these negative results could be that these
antibodies were administered in patients with mild-to-




















Figure 1 Immunotherapy approach to beta-amyloid clearance. Aβ,
system; mAb, monoclonal antibody.advanced. Secondary analysis of solanezumab phase 3
data indicated potential clinical benefits in patients with
mild AD [13]. An additional phase 3 study is currently
underway to confirm these findings (ClinicalTrials.gov
NCT01900665).
Preclinical evidence suggests that peripherally admin-
istered antibodies can enter the central nervous system
and bind to Aβ, where it is eliminated via Fc receptor-
mediated clearance by microglial cells [11]. However,
Aβ antibodies in brain parenchyma only reached 0.1%
of the antibody concentration in serum due to the low
passage of antibodies across the blood–brain barrier.
Antibodies also have to pass through further barriers
to reach intracellular compartments. Consequently,
intraneuronal Aβ antibody concentrations may not be
sufficient to reduce intracellular Aβ, impacting efficacy.
This also makes it difficult to optimize dosing. Other
passive immunotherapy compounds currently being
investigated in clinical trials include gantenerumab,
crenezumab, BAN2401, GSK933776, AAB-003, SAR228810,
and BIIB037/BART [13].
The concept of active Aβ immunotherapy for AD was
first introduced in 1999 [12]. Vaccination of APP trans-
genic mice with an Aβ1–42 peptide prior to amyloid de-
posits effectively blocked amyloid accumulation as mice
aged, and treatment in the older mice reduced the pro-
gression of AD-like neuropathologies [12]. AN1792, a
synthetic Aβ1–42 peptide co-administered with a QS21
adjuvant, was the first active Aβ immunotherapy tested
in clinical trials. However, a phase 2 trial demonstrated
that only 19.7% of patients with mild-to-moderate AD
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meningoencephalitis was observed in 6% of patients
[16]. An Aβ-specific T-cell response (T-helper type 1
CD4+) is believed to have occurred, given that AN1792
consists of full-length Aβ1–42 that carries T-cell epitopes
[17,18]. Results from this study showed that patients
with an antibody response demonstrated significantly
better scores in certain memory functions of the neuro-
psychological test battery, but no difference in cognitive
and disability scores compared with the placebo group
[15]. As T-cell epitopes mainly reside in the central pro-
portion of Aβ1–42 [19], a number of approaches have
been developed comprising the Aβ N-terminus (B-cell
epitopes) to avoid a T-cell response and have shown
promise as second-generation active immunotherapeutic
options for modifying AD. These compounds involve ad-
ministering short Aβ peptides, fragmented peptides, or
peptide mimetics to activate the patient’s immune sys-
tem. Aβ peptides are usually conjugated to a carrier,
such as a virus-like particle or keyhole limpet
hemocyanin (KLH), and administered with an adjuvant
to encourage stimulation of the immune response [20].
Therefore, due to the component differences between
the active immunotherapies, no direct comparisons can
be made with respect to doses or adjuvant effects. The
antibody affinity achieved may also be different across
vaccines, and may improve on repeated injections dem-
onstrating affinity and avidity maturation.
In comparison, tau immunotherapy is a relatively
underexplored therapeutic target for AD. This review
will thus mainly focus on the second-generation active
immunotherapy options for targeting the Aβ peptide in
AD. Table 1 presents the Aβ-targeted active immunotherapyTable 1 Active amyloid-beta immunotherapies in developmen
Compound Sponsor Epitope/carrie
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anus toxoid
Aβ, amyloid-beta protein; AD, Alzheimer’s disease; i.m., intramuscular; s.c., subcutaneapproaches currently being investigated and describes their
mechanism of action and key clinical data.
Amyloid-beta protein immunotherapy
CAD106
CAD106 is a second-generation, Aβ-based active immuno-
therapy comprising multiple copies of Aβ1–6 peptide coupled
to a carrier that contains 180 copies of the bacteriophage Qβ
coat protein [21]. CAD106 is designed to stimulate a strong
B-cell response and carrier-induced T-cell help, without
activating an Aβ-specific T-cell response [10,21]. In animal
models, CAD106 effectively induces Aβ antibodies with-
out potential mechanism-related side effects caused by
stimulation of Aβ-specific T cells [10]. As all of the main
IgG subclasses were generated, CAD106 has the potential
to stimulate the entire range of effector functions. In
APP23/24 transgenic mice, CAD106 effectively reduced
amyloid accumulation (Figure 2) [10]. CAD106 was more
effective when administered in the early stages of amyloid
accumulation, with the greatest effect being when admin-
istered before amyloid deposition starts. The elevation of
vascular Aβ observed in some mice studies did not lead to
an increase in microhemorrhages [10]. Of note, CAD106-
induced antibodies from rhesus monkeys were also shown
to protect from Aβ toxicity in vitro [10].
A phase 1, 52-week, placebo-controlled study (study
number 2101; ClinicalTrials.gov NCT00411580) in patients
with mild-to-moderate AD (Mini-mental State Examination
16 to 26) showed that three subcutaneous (s.c.) injections
of CAD106 (50 μg, n= 24; or 150 μg, n= 22) had a favorable
safety profile, without an Aβ-specific T-cell response, and an
acceptable antibody response (Figure 3) [21]. The proportion































r epitopes from tet-
N/A Preclinical Early AD
ous.
Figure 2 Amyloid deposition in the neocortex of APP24 mice after treatment with CAD106 and vehicle. (A) Treatment with vehicle. (B)
















































































Figure 3 Mean amyloid-beta protein-specific antibody response with CAD106, by IgM and IgG titers. (A) IgM titers. (B) IgG titers. Aβ,
amyloid-beta protein. Reprinted from [21]. © 2012, with permission from Elsevier.
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responder threshold was higher in the 150 μg group
versus the 50 μg group (82% vs. 67%) [21]. Results from
selected plasma samples showed that free Aβ decreased
in parallel with an increase in total Aβ concentration
[21]. The binding of CAD106-induced Aβ antibodies
from patients to amyloid plaque cores on brain sections
from APP23 transgenic mice and from a patient with
AD was increased at week 8 compared with baseline
and correlated with Aβ IgG titers [21]. No significant
differences were observed between CAD106 and placebo
for cerebrospinal fluid (CSF) total tau, phospho-tau, Aβ40
and Aβ42 biomarkers [21]. The lack of significance could
be attributed to the small sample size, or the antibody
exposure of 100 days may have been too short to show a
clinical effect [21].
In two 52-week, phase 2a studies in patients with mild
AD (Mini-mental State Examination 20 to 26), 150 μg
CAD106 was administered subcutaneously at weeks 0, 6,
and 12 (study 2201; ClinicalTrials.gov NCT00733863),
or either subcutaneously or intramuscularly at weeks 0,
2, and 6 (study 2202; ClinicalTrials.gov NCT00795418)
[22]. In both studies, approximately 90% of patients de-
veloped an antibody response [23], with the highest total
plasma Aβ concentrations being observed in patients
with a strong antibody response [24]. Results from these
studies showed that the total plasma Aβ concentration
increased in parallel to Aβ-specific IgG development
[24]. Consistent with results from the phase 1 study
[21], CSF sampling at 8 weeks after the third injection
did not show significant differences in tau, phospho-tau,
isoprostane [24], or Aβ40 and Aβ42 biomarkers (unpub-
lished observations). However, the timing of CSF sam-
pling was driven by safety monitoring rather than
optimized biomarker detection. In open-label extensions
to these studies (ClinicalTrials.gov NCT00956410;
NCT01023685), patients received four additional injec-
tions of CAD106 at 12-week intervals (weeks 56, 68, 80,
and 92) by s.c. or intramuscular (i.m.) routes. Results
from the core studies showed that the mean total plasma
Aβ concentration increased, probably due to the longer
half-life of Aβ in the periphery upon binding to anti-
bodies [24]. The additional four injections induced a
similar antibody titer to the initial three injections, but
with a higher increase in total plasma Aβ. The increase
of levels over time is consistent with improved affinity of
IgG to the target, and confirms that CAD106 is suitable
for long-term chronic treatment in AD [22]. Study 2202
data also suggested that i.m. administration of CAD106
generates a more robust IgG response than s.c. adminis-
tration [23]. An additional phase 2 study investigating
up to seven repeated i.m. injections of CAD106 (150 or
450 μg with an adjuvant vs. placebo) in 121 patients with
mild AD (Mini-mental State Examination 20 to 26) hasrecently been completed (study 2203; ClinicalTrials.gov
NCT01097096) [25].
Safety and tolerability of CAD106 immunotherapy
Results from previous studies have shown that CAD106
has a favorable safety profile, with no unexpected findings,
and does not stimulate an Aβ-specific T-cell response
[21,22]. In the phase 1 study, nearly all patients (97%,
n = 56/58) experienced an adverse event (Table 2) [21].
Nasopharyngitis (10/24 CAD106-treated patients) and
injection site erythema (14/22 CAD106-treated patients)
were the most frequently reported adverse events in the
50 μg and 150 μg cohorts, respectively [21]. Nine patients
reported serious adverse events, but none were thought to
be related to CAD106. No clinical or subclinical cases of
meningoencephalitis, aseptic meningoencephalitis, or
vasogenic edema were reported [21], and no differences
in vital signs, hematological tests, blood chemistry,
urinalysis, or laboratory parameters were seen between
the CAD106-treated patients versus placebo-treated
patients [21]. Moreover, data from the phase 2 studies
demonstrated that tolerability was slightly improved
with i.m. administration, which was selected for further
ongoing studies [26]. Brief self-limiting injection-related
reactions – either local (for example, erythema) or systemic
(for example, fatigue) – were observed in the majority of
patients [25], as commonly expected with successful
vaccinations. There was one incidence of intracerebral
hemorrhage that did not appear to be related to the
level of Aβ titers, but could be potentially related to
cerebral amyloid angiopathy [26].
ACC-001
ACC-001 (vanutide cridificar) is a conjugate of multiple
copies of Aβ1−7 peptide linked to a nontoxic variant of
diphtheria toxin (CRM197), which is administered
intramuscularly [27,28]. Data from preclinical studies in
nonhuman primates showed that ACC-001 generates
N-terminal Aβ antibodies without inducing an Aβ-
directed T-cell response [27]. Ongoing ACC-001 phase
2 clinical trials in mild-to-moderate AD and early AD
are investigating dose-ranging, safety, immunogenicity,
and long-term treatment in western and Japanese pa-
tients (ClinicalTrials.gov NCT01284387; NCT01227564;
NCT00955409; NCT00960531; NCT01238991 (Japanese)).
Some clinical trials have already been completed (Clinical-
Trials.gov NCT00479557; NCT00498602; NCT00752232
(Japanese); NCT00959192 (Japanese)).
Data from a study in Japanese patients with mild-to-
moderate AD (ClinicalTrials.gov NCT00752232) demon-
strated that repeated i.m. administration of ACC-001
(3 μg, 10 μg, and 30 μg) with adjuvant QS-21 (50 μg) at
3-monthly intervals up to 1 year elicited high-titer and
sustained Aβ IgG antibody responses, with no difference
Table 2 Adverse events (>10% of patients in any group) from a phase 1 study of CAD106 in patients with
mild-to-moderate Alzheimer’s disease during the 52-week study period
Cohort 1 Cohort 2
Event CAD106 50 μg (n = 24) Placebo (n = 7) CAD106 150 μg (n = 22) Placebo (n = 5)
Any serious adverse event 4 (17) 1 (14) 4 (18) 0
Any adverse events 23 (96) 6 (86) 22 (100) 5 (100)
Injection site erythema 1 (4) 1 (14) 14 (64) 0
Nasopharyngitis 10 (42) 2 (29) 3 (14) 0
Fatigue 7 (29) 0 4 (18) 1 (20)
Nausea 4 (17) 2 (29) 3 (14) 0
Chills 1 (4) 0 6 (27) 0
Headache 5 (21) 0 4 (18) 1 (20)
Diarrhea 3 (13) 1 (14) 0 1 (20)
Vomiting 2 (8) 1 (14) 3 (14) 1 (20)
Fever 1 (4) 0 4 (18) 0
Injection site pain 0 0 4 (18) 0
Myalgia 4 (17) 0 0 0
Fall 3 (13) 1 (14) 1 (5) 0
Back pain 3 (13) 0 3 (14) 0
Rhinitis 3 (13) 0 0 0
Data presented as n (%). Reprinted from [21]. © 2012, with permission from Elsevier.
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QS-21 was essential to stimulate high-titer responses.
ACC-001 at all dose levels with/without QS-21 was gen-
erally safe and well tolerated, and the safety profile was
similar to that of western populations [28]. Adverse
events observed in this trial are presented in Table 3.
Similar to phase 1 results of CAD106 [29], no significant
differences were observed in cognitive evaluations, but
this may be due to the small sample size (n = 40) and
interpatient variability [28].
The ongoing phase 2 ACCTION study (ClinicalTrials.
gov NCT01284387) is among the first AD studies to use
amyloid positron emission tomography as an enrichment
strategy to increase diagnostic certainty. The authors
concluded that, despite its challenges, amyloid positron
emission tomography is an effective tool for sample
enrichment in mild-to-moderate AD trials, and CSF
sampling is also feasible. Baseline and longitudinal
amyloid positron emission tomography, volumetric
magnetic resonance imaging, and CSF data may thus
provide valuable data for AD trials and may support
treatment response determination [30].
Affitope
AD01 and AD02 (Affitope) are KLH vaccines with short
(six amino acids) peptides that mimic the N-terminus of
Aβ [31]. These compounds were designed to exhibit a
favorable safety profile because they are non-endogenous,
and will avoid development of tolerance. Moreover, thesmall size averts autoreactive T-cell activation, and the
controlled specificity prevents cross-reactivity with APP
[31]. There are limited data available for this compound,
but results from a phase 1 study showed a favorable safety
profile with both AD02 and AD01 [32]. AD02 has been
selected for development in a phase 2, dose-finding trial in
patients with early AD to investigate clinical/immunological
activity and tolerability (ClinicalTrials.gov NCT01117818).
AD03 (MimoVax, Vienna, Austria), a KLH vaccine that
additionally targets modified Aβ peptides, is currently in
phase 1b development (ClinicalTrials.gov NCT01568086)
and has previously been shown to significantly reduce
amyloid plaque load in APP mice [33].
ACI-24
ACI-24 is a tetra-palmitoylated Aβ1−15 peptide reconstituted
in a liposome [34]. After two intraperitoneal inoculations of
ACI-24 in double-transgenic APP × PS-1 mice, significant
levels of systemic Aβ1−42 antibodies were detected that were
predominantly of the IgG class (mainly IgG1, IgG2b, and
IgG3), indicating a preferential T-helper type 2 response.
Complete restoration of cognitive, nonspatial memory as
measured by a novel object recognition test was observed
after six inoculations at 2-week intervals. Aβ1−42-specific
IgG antibody titers were positively correlated to the object
recognition test index. In addition, ACI-24 led to a
significant decrease in insoluble, plaque-related Aβ1−40
and Aβ1−42, and soluble Aβ1−42, and to a lesser extent
soluble Aβ1−40. No significant signs of inflammation –
Table 3 Adverse events (>2% of patients overall) from a phase 2a study of ACC-001 in Japanese patients with
mild-to-moderate Alzheimer’s disease [28]
Event ACC-001 + QS-21 ACC-001 QS-21 (n = 6) PBS (n = 4)
3 μg (n = 6) 10 μg (n = 6) 30 μg (n = 6) 10 μg (n = 6) 30 μg (n = 6)
Any serious adverse eventa 1 (16.7) 0 1 (16.7) 0 0 0 0
Any adverse events 6 (100.0) 4 (66.7) 5 (83.3) 6 (100.0) 6 (100.0) 6 (100.0) 3 (75.0)
Nasopharyngitis 2 (33.3) 2 (33.3) 2 (33.3) 0 3 (50.0) 1 (16.7) 2 (50.0)
Injection site erythema 0 2 (33.3) 0 0 1 (16.7) 0 0
Dental caries 0 1 (16.7) 0 1 (16.7) 1 (16.7) 0 1 (25.0)
Protein urine present 1 (16.7) 1 (16.7) 0 0 1 (16.7) 0 0
Glucose urine 1 (16.7) 0 0 1 (16.7) 0 0 1 (25.0)
Cataract 1 (16.7) 0 0 1 (16.7) 0 0 1 (25.0)
Contusion 1 (16.7) 0 0 1 (16.7) 0 1 (16.7) 0
Back pain 0 0 1 (16.7) 0 1 (16.7) 0 0
Blood triglyceride increased 0 1 (16.7) 1 (16.7) 0 0 1 (16.7) 0
Injection site pain 0 1 (16.7) 1 (16.7) 0 0 0 0
Pyrexia 0 1 (16.7) 0 0 1 (16.7) 0 0
Delirium 1 (16.7) 0 0 0 0 1 (16.7) 0
Blood pressure increased 0 0 0 1 (16.7) 0 1 (16.7) 0
Eczema 0 1 (16.7) 0 0 0 0 1 (25.0)
Data presented as n (%). PBS, phosphate-buffered saline. aAll patients.
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necrosis factor alpha, interleukin-1β, interleukin-6, and
interferon gamma), microglia activation or astrogliosis –
were detected [34]. A phase 1/2a clinical trial investigating
the safety and efficacy of ACI-24 in patients with mild-to-
moderate AD is currently ongoing (EudraCT 2008-
006257-40).
V950
V950 is a multivalent Aβ peptide vaccine [35]. Data from
preclinical studies have shown that V950 results in the
production of Aβ antibodies in the serum and CSF that
recognize pyroglutamate-modified and other N-terminally
truncated Aβ fragments [35]. A phase 1 dose-escalating
study of V950 in patients with mild-to-moderate AD to
evaluate the safety, tolerability, and immunogenicity of i.
m. V950 with ISCOMATRIX™ adjuvant (ClinicalTrials.gov
NCT00464334) at 0, 2, and 6 months has been completed.
Results are available online [36] and no further studies
have been initiated.
UB-311
UB-311 is an equimolar mixture of two synthetic peptides,
consisting of highly active UBITh® helper T-cell epitopes,
coupled to the Aβ1–14 peptide. The vaccine is designed to
stimulate the T-helper type 2 regulatory response over the
T-helper type 1 proinflammatory response using a propri-
etary vaccine delivery system (CpG oligonucleotide), andis likely to prevent cross-reactivity with different but simi-
lar antigens [37]. A phase 1 clinical trial of intramuscularly
administered UB-311 at weeks 0, 4, and 12 in Taiwanese
patients with mild-to-moderate AD has been completed
(ClinicalTrials.gov NCT00965588), demonstrating safety
and tolerability; however, results have not yet been pub-
lished. In addition, United Biochemical, Inc. (Hauppauge,
NY, USA) is currently initiating a phase 2 study.
Lu AF20513
Lu AF20513 is an Aβ1−12 peptide in which the T-helper
cell epitopes of Aβ42 are replaced with two foreign
T-helper epitopes from the tetanus toxin, which stimu-
late existing memory T-helper cells to promote Aβ anti-
body production from B cells [38]. Most adults have
memory T cells that recognize the tetanus toxin, as they
are inoculated against the bacterium earlier in life. In
transgenic mice with early-stage AD-like pathology, Lu
AF20513 produced Aβ antibodies and induced robust
nonself T-cell responses that reduced AD-like pathology
without inducing microglial activation and enhancing
astrocytosis or cerebral amyloid angiopathy [38]. Strong
humoral immunity was induced in mice, guinea pigs,
and monkeys. Interestingly, a single injection of Lu
AF20513 activated pre-existing CD4+ T cells specific to
foreign T-helper epitopes, inducing a rapid and strong
T-helper cell and Aβ response, therefore presenting a
potential solution to overcoming the limited ability of
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pre-existing anti-P30/P2 memory T-helper cells [38]. In
addition, Lu AF20513 suppressed amyloid plaque for-
mation and accumulation of soluble forms of Aβ40/42.
Furthermore, Aβ antibodies also protected neuronal
cells from Aβ42 oligomer-mediated and fibril-mediated
toxicity, and prevented the development of cored and
diffuse plaques. The number of amyloid-containing
blood vessels did not increase and no microhemor-
rhages were reported. Preclinical data from this study
support the transition of this vaccine to human clinical
trials.
DNA amyloid-beta protein immunotherapy
DNA Aβ immunotherapy is currently being investigated
in preclinical studies [39-42]. This approach involves
using a gene gun to inject DNA encoding Aβ42, which is
subsequently translated to the Aβ peptide triggering a
respective immune response. Data from transgenic
mouse models have demonstrated that DNA Aβ42
immunotherapy effectively reduces Aβ42 levels in the
brain by 41% and in plaques by 50% [41]. DNA Aβ
immunotherapy induces a strong polarized T-helper
type 2 cellular immune response [39,41]. In vitro, the
absence of T-cell proliferation in B6SJLF1/J mice
immunized with a full-length DNA42 trimer compared
with B6SJLF1/J mice immunized with an Aβ42 peptide
supports the safety of this approach [40]. As full-length
DNA Aβ42 immunotherapies contain B-cell and T-cell
epitopes, a wider antibody response against Aβ with a
broader variety of antibody responses may be observed
compared with Aβ-peptide immunotherapies, especially
as T-cell help is required to maintain and further the
humoral immune response. However, the antibody
response to DNA immunotherapy is much lower com-
pared with peptide immunotherapy, but this can be
improved with prime-boost regimens [39]. Moreover, a
DNA vaccine targeting a wide range of Aβ species
including AβpE3-42, Aβ oligomers, and Aβ fibrils has
shown promising results in preclinical studies [43].
These data support investigating DNA Aβ immunother-
apy in clinical trials.
Tau immunotherapy
At present, tau-directed therapies are not as advanced as
other options currently in development for disease
modification of AD. The success of a tau-targeted therapy
is complicated by the fact that tau protein is intracellular
[44]; however, numerous studies have shown neuronal
uptake of antibodies [45-47]. Moreover, inflammatory
changes and cellular stress in response to tau pathology
may facilitate antibody uptake primarily into diseased
neurons, potentially reducing unwanted side effects.
Extracellular spreading of tau pathology may also beblocked by antibodies. Recent data have demonstrated
that tau monoclonal antibodies blocked development of
tau seeding activity detected in brain lysates, reduced
microglial activation, and improved cognitive deficits in
P301S tau transgenic mice [48]. Preclinical data in
various mouse models suggest that tau-targeted im-
munotherapies with phosphorylated peptides reduce
levels of tau phosphorylation and NFT burden when
treatment is started before or around the onset of
NFT pathology [49,50], indicating that clearance of
early-stage pathological conformers may be of thera-
peutic benefit [49]. Furthermore, in a htau/PS1 tangle
mouse model, tau-targeted immunotherapy has been
shown to prevent severe cognitive impairment that
correlated with extensive clearance of abnormal tau
[51]. In another study, suppression of tau expression
in a different transgenic P301L mouse model was
seen to improve memory, although NFTs remained
[52]. The lack of clarity regarding which conformer of
tau should be targeted therefore remains an issue
[53]. Overall, results from these studies support the
feasibility of targeting pathological tau conformers in
patients with AD.AADvac1
AADvac1 (Axon Neuroscience, Bratislava, Slovak Re-
public), a tau peptide conjugated to a KLH that is
administered with an aluminum hydroxide (Alhydrogel)
adjuvant, is the first vaccine targeting misfolded tau pro-
tein that has been clinically developed [54]. Vaccination
of transgenic rats and mice with passive and active forms
of AADvac1 significantly improved neurobehavioral
deficits, and reduced neurofibrillary degeneration and
mortality [54]. The active AADvac1 vaccine is currently
being investigated in a 3-month, phase 1, randomized,
placebo-controlled clinical trial (ClinicalTrials.gov
NCT01850238) to assess tolerability, safety, and efficacy
in patients with mild-to-moderate AD.ACI-35
ACI-35 (AC Immune, Lausanne, Switzerland) is a lipo-
somal vaccine containing a synthetic peptide (16 amino
acids) corresponding to human protein tau sequence
393 to 408, with phosphorylated residues S396 and
S404, using the same technology as ACI-24. In wild-type
and tau.P301L transgenic mice, ACI-35 elicited rapid
and robust polyclonal antibody responses specific for
phosphorylated tau [55]. Long-term safety of the vaccine
was also demonstrated by the improvement of clinical
characteristics and lack of inflammation in the brain.
These data indicate ACI-35 could be an effective and
safe treatment for patients with AD.
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immunotherapy
Benefits
Contrary to passive immunotherapy, which requires frequent
re-administrations, active immunotherapy stimulates a natural
immune response that can achieve persistent Aβ antibody
titer levels with a low antigen dose and a minimal number of
administrations. The steady antibody titers may be beneficial
in achieving sufficient intraneuronal antibody concentrations
targeting intracellular Aβ. This approach also has the
potential to induce a polyclonal response against multiple
epitopes, which may be relevant for improved efficacy. In
addition, peak titers are reached gradually with a lower
maximum plasma concentration compared with intravenous
infusion of monoclonal antibodies, which may be important
for safety. The risk of anaphylaxis reactions is also reduced
with s.c. or i.m. administration of active immunotherapies.
Furthermore, fewer injections may make treatment suitable
for long-term therapy in primary care or in the home setting,
promote improved compliance, and significantly reduce cost.
Lastly, affinity maturation with repeated injections over time
is also expected to lead to better quality antibodies and the
possibility of an improved therapeutic response.
Challenges
There are some challenges to overcome with active im-
munotherapy. First, the mechanism of action relies on
the patient’s own immune response, which varies amongst



















Risk of depatients, who quite often have weakened immune systems
resulting in a diminished serological response to the antigen.
Although achieved with current active immunotherapies in
development, avoidance of Aβ-specific T cells to prevent
pathological autoreactive T-cell responses is still an important
safety consideration that must be assessed through long-term
clinical follow-up. Given the complexity and interindividual
variability of the immune response involved, a more complete
understanding of the relationship of this response to active
immunotherapy dose, adjuvants, regimen, route of administra-
tion, and impact on clinical outcomes will need to be explored
during phase 2 clinical trials.
With repeated administrations, tolerance may develop
over time and should be monitored especially with a
self-antigen. Another concern to consider when using a
self-antigen is the potential to develop an autoimmune
response. Although no such incidences have been re-
ported with active amyloid immunotherapy, amyloid-
related imaging abnormalities have been observed in
patients with AD treated with passive amyloid immuno-
therapy. The etiology of amyloid-related imaging abnor-
malities remains unclear but the prevailing data support
vascular amyloid as a common pathophysiological
mechanism leading to increased vascular permeability.
Patients should thus be carefully monitored with brain
imaging for amyloid-related imaging abnormalities and
any associated clinical features [56]. The benefits and
challenges with active immunotherapy are summarized
in Table 4.es for alzheimer’s disease
mune response







s are reached gradually
aturation of antibodies
risk of anaphylaxis reactions
patients’ own immune response
tive T-cell responses need to be avoided
standing of the relationship of responses to clinical outcomes is required
n of antibody responses in older patients
ent of tolerance to be avoided
veloping an autoimmune response
veloping amyloid-related imaging abnormalities
Winblad et al. Alzheimer's Research & Therapy 2014, 6:7 Page 10 of 12
http://alzres.com/content/6/1/7Conclusion
The need to develop disease-modifying drugs that stabilize
or slow the AD pathological process leading to neurode-
generation is recognized worldwide, and most initial drug
development programs have largely focused on compounds
targeting the Aβ pathway. Active immunotherapies may
play an important future role in long-term treatment, and
several of these experimental therapies are showing promis-
ing early results in terms of antibody response and safety.
Recent clinical trial failures with passive immunotherapy
could be because the interventions might have been admin-
istered too late in the disease course, suggesting that active
immunotherapy trials should be directed to individuals with
earlier-stage disease. The idea that treatment initiation prior
to dementia onset in humans may be most likely to succeed
is supported by the observation that active immuno-
therapies appear to be most effective in early stages
of amyloid accumulation in preclinical models.
Whether early intervention studies are best conducted
in sporadic or familial forms of AD remains an open
question because different Aβ antibody concentrations
and treatment durations may be needed for sporadic
and familial AD due to possible differences in the
pathological cascade leading to dementia. In addition,
therapies targeting a single pathway may not be able
to demonstrate optimal efficacy, and combination
therapies targeting both Aβ and tau aggregates may
ultimately be required. Once the interplay between
AD pathologies is better understood, active immuno-
therapies may prove to be the ideal therapeutic plat-
form for delivering cost-effective and long-term
treatments that slow or halt progression in AD.Note: This article is part of a series on Immunotherapy in
Alzheimer’s disease, edited by Philip Scheltens. Other articles in this
series can be found at http://alzres.com/series/immunotherapy.Abbreviations
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